KRAS and non-small cell lung carcinoma: In 2013, a new pocket was identified in which mutant KRAS protein binds to GDP near the effector binding switch II area; the identification of this pocket allows KRASG12C to be targeted for the treatment of KRASG12C-mutant NSCLC [98].